Abemaciclib Drives the Therapeutic Differentiation of Acute Myeloid Leukemia Stem Cells

To screen drugs to overcome differentiation blockade for acute myeloid leukemia, researchers conducted screening of 2040 small molecules from a library of US FDA-approved drugs and found that the cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerted high anti-leukemic activity.